Regulatory Affairs & Submissions · Healthcare & Life Sciences
Should you build or buy Medical Device Post-Market Surveillance Platform?
Medical device post-market surveillance (PMS) software helps device manufacturers meet ongoing regulatory obligations under EU MDR/IVDR and FDA PMSR guidance by systematically gathering and analyzing post-market safety data. It manages literature surveillance, adverse event signal detection, trend analysis, and the generation of Periodic Safety Update Reports (PSURs) and Post-Market Surveillance Reports (PMSRs) that regulators require throughout a device's commercial life.
The build-vs-buy decision for Medical Device Post-Market Surveillance turns on how far AI-powered literature review and signal detection tools have lowered the cost of building core analytical capabilities in-house, weighed against the compliance documentation and validated system status that EUDAMED integration and PSUR generation still require; the specifics of your team's data science capacity and regulatory audit obligations decide it.
Build it, buy it, or bridge?
When building makes sense
The build case for post-market surveillance has strengthened meaningfully in the past two years, primarily because AI literature review tools have changed the economics of systematic review automation. What once required expensive PMS platform subscriptions — automated literature screening against PubMed, clinical registries, and adverse event databases — can now be partially replicated with tools like Elicit, custom LLM-based screening pipelines, or platforms that position themselves as components rather than full suites. Signal detection analytics are similarly buildable with standard ML and accessible adverse event data sources. The realistic build target is the analytical intelligence layer: custom signal thresholds per device class, literature scope calibrated to your risk management file, and trend reports that feed directly into product development decisions rather than just satisfying a regulatory checkbox. The constraint is the compliance documentation: EUDAMED integration and the validated system status required for PSUR and PMSR generation haven't been widely self-built in production.
When buying makes sense
Buying makes sense when regulatory obligations are the immediate driver — when PSUR deadlines or EUDAMED submission timelines are in front of you and the priority is defensible, auditable compliance rather than analytical sophistication. Platforms like Smarteeva, Sparta Systems TrackWise Digital, and Rimsys ship with PSUR authoring templates, EUDAMED integration, and validated report generation workflows that satisfy EU MDR and FDA PMSR obligations without requiring the compliance documentation burden of a self-built system. Buying also makes sense for companies whose device portfolio and adverse event volume don't justify the engineering investment of a custom analytics stack — if your team is running one or two mature product lines with moderate complaint and literature volume, a vendor platform gives you complete PMS coverage without building infrastructure you'd use minimally.
The desk read
Post-market surveillance obligations under EU MDR and FDA PMSR guidance define a standardized framework: periodic safety update reports, trend analysis, signal detection, and literature surveillance. The framework is standardized, but a device maker's specific adverse event coding taxonomies, signal thresholds, and literature search scope are customized per device class and risk management file. That customization creates meaningful distance between vendor defaults and what a device company actually needs from its PMS data.
AI literature review tools have changed this calculus more than any other recent development. Systematic review automation, which once required expensive platform subscriptions, can now be partially replicated with tools like Elicit and custom LLM-based screening pipelines, and platforms like DistillerSR compete directly with internal builds in some organizations. Signal detection analytics are buildable with standard ML. The friction is the regulatory audit trail and validated system status required for EUDAMED integration and PSUR generation. For companies with capable data science teams, the pieces are there; the question is whether stitching them together with the required compliance documentation costs more than licensing a platform that's already done it.
Frequently asked
What is a Medical Device Post-Market Surveillance Platform?
Medical device post-market surveillance software helps device manufacturers meet ongoing regulatory obligations under EU MDR/IVDR and FDA PMSR guidance by systematically gathering and analyzing post-market safety data. It manages literature surveillance, adverse event signal detection, trend analysis, and PSUR and PMSR generation that regulators require throughout a device's commercial life.
When does building a Medical Device Post-Market Surveillance Platform make sense?
Building makes sense when your team has data science capability and wants to build analytical intelligence — custom signal detection, AI-assisted literature screening, and trend analytics that feed product development. AI literature review tools have significantly lowered this bar. The compliance documentation for EUDAMED integration and PSUR generation is still the friction point.
When does buying a Medical Device Post-Market Surveillance Platform make sense?
Buying makes sense when PSUR deadlines or EUDAMED submission timelines are pressing and you need validated, auditable compliance outputs quickly. Vendor platforms carry pre-built PSUR templates and regulatory integrations that a self-built system would need to replicate with full compliance documentation.
What are the main Medical Device Post-Market Surveillance vendors?
Representative vendors include DistillerSR, Smarteeva, Sparta Systems (TrackWise Digital), Rimsys. B4 Pro scores the full set.
How has AI changed the PMS software market for device companies?
AI has most visibly changed the literature surveillance piece — systematic review automation that once required platform subscriptions can now be partially replicated with LLM-based screening tools. This shifts the build-vs-buy calculus for companies with data science teams, making the analytical layers of PMS increasingly viable to build while the validated compliance backbone (PSUR generation, EUDAMED integration) remains the hard part to self-build.